Top

Published in:

Open Access 01-12-2020 | Diabetes | Research article

Natural killer cell levels in adults living with type 2 diabetes: a systematic review and meta-analysis of clinical studies

Authors: Vuyolwethu Mxinwa, Phiwayinkosi V. Dludla, Tawanda M. Nyambuya, Kabelo Mokgalaboni, Sithandiwe E. Mazibuko-Mbeje, Bongani B. Nkambule

Published in: BMC Immunology | Issue 1/2020

Abstract

Background

Chronic immune activation and hyperglycaemia are a hallmark of type 2 diabetes mellitus (T2D) while natural killer (NK) cells are involved in the pathogenesis of T2D. Dysregulated NK cell responses are associated with an increased risk of cardiovascular disease in patients living with T2D.

Objective

To provide a comprehensive and systematic evidence-based estimate on the levels of NK cells in patients living with T2D.

Results

This systematic review and meta-analysis included 13 studies reporting on 491 adult patients with T2D and 1064 nondiabetic controls. The pooled effect estimates showed increased levels of NK cells in adult patients with T2D compared to controls (MD: 0.03 [− 3.20, 3.26], I² = 97%, p < 0.00001).

Conclusion

Overall, the evidence presented in this systematic review shows that the changes in NK cells in patients living with T2D are still unclear and further studies are needed.

Available only for authorised users

World Health Organization. The top 10 causes of death. 2018. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed on the 20 Jan 2020.

World Health Organization. Global report on diabetes. Isbn. 2016;978:88 ISBN 978 92 4 156525 7.

Glezeva N, Chisale M, McDonald K, Ledwidge M, Gallagher J, Watson CJ. Diabetes and complications of the heart in sub-Saharan Africa: an urgent need for improved awareness, diagnostics and management. Diabetes Res Clin Pract. 2018;137:10–9. https://doi.org/10.1016/j.diabres.2017.12.019.PubMedCrossRef

Sowers JR. Obesity as a cardiovascular risk factor. In: American journal of medicine; 2003. p. 37–41.

Whitmore C. Type 2 diabetes and obesity in adults. Br J Nurs. 2010;19:880–882–6.PubMedCrossRef

Mittendorfer B. Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking. Curr Opin Clin Nutr Metab Care. 2011;14:535–41.PubMedCrossRef

Wang M, Chen F, Wang J, Zeng Z, Yang Q, Shao S. Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients. Clin Immunol. 2018;197:77–85. https://doi.org/10.1016/j.clim.2018.09.005.PubMedCrossRef

Margetic S. Inflammation and hemostasis. Biochem Med. 2012;22:49–62.CrossRef

Mahlangu T, Dludla PV, Nyambuya TM, Mxinwa V, Mazibuko-Mbeje SE, Cirilli I, et al. A systematic review on the functional role of Th1/Th2 cytokines in type 2 diabetes and related metabolic complications. Cytokine. 2020;126:154892. https://doi.org/10.1016/j.cyto.2019.154892.PubMedCrossRef

10.

Nyambuya TM, Dludla PV, Mxinwa V, Nkambule BB. T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus: a systematic review and meta-analysis. Clin Immunol. 2020;210:108313. https://doi.org/10.1016/j.clim.2019.108313.PubMedCrossRef

11.

Nyambuya TM, Dludla PV, Mxinwa V, Nkambule BB. Obesity-induced inflammation and insulin resistance: a mini-review on T-cells. Metab Open. 2019;3:100015. https://doi.org/10.1016/j.metop.2019.100015.CrossRef

12.

Bénézech C, Jackson-jones LH. ILC2 orchestration of local immune function in adipose tissue. Front Immunol. 2019;10:1–6.CrossRef

13.

Sullivan TEO, Rapp M, Fan X, Walzer T, Dannenberg AJ, Sun JC, et al. Adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance article adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance. Immunity. 2016;45:428–41. https://doi.org/10.1016/j.immuni.2016.06.016.CrossRef

14.

Piątkiewicz P, Miłek T, Bernat-Karpińska M, Ohams M, Czech A, Ciostek P. The dysfunction of nk cells in patients with type 2 diabetes and colon cancer. Arch Immunol Ther Exp. 2013;61:245–53.CrossRef

15.

Åkesson C, Uvebrant K, Oderup C, Lynch K, Harris RA, Lernmark Å, et al. Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clin Exp Immunol. 2010;161:48–56.PubMedPubMedCentral

16.

Berrou J, Fougeray S, Venot M, Chardiny V, Gautier J-F, Dulphy N, et al. Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One. 2013;8:e62418. https://doi.org/10.1371/journal.pone.0062418.PubMedPubMedCentralCrossRef

17.

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes : a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018:1–19. https://doi.org/10.1186/s12933-018-0728-6.

18.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000;283:2008–12.PubMedCrossRef

19.

Xiaohong L, Gao Y, Dong T, Yang L. Role of Natural Killer T (NKT) cells in type II diabetes-induced vascular injuries. Med Sci Monit. 2018;24:8322–32. https://doi.org/10.12659/MSM.912446.CrossRef

20.

Olson NC, Doyle MF, de Boer IH, Huber SA, Jenny NS, Kronmal RA, et al. Associations of circulating lymphocyte subpopulations with type 2 diabetes: cross-sectional results from the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2015;10:1–14.

21.

Simar D, Versteyhe S, Donkin I, Liu J, Hesson L, Nylander V, et al. DNA methylation is altered in B and NK lymphocytes in obese and type 2 diabetic human. Metabolism. 2014;63:1188–97. https://doi.org/10.1016/j.metabol.2014.05.014.PubMedCrossRef

22.

Singh K, Martinell M, Luo Z, Espes D, Stålhammar J, Sandler S, et al. Cellular immunological changes in patients with LADA are a mixture of those seen in patients with type 1 and type 2 diabetes. Clin Exp Immunol. 2019;197:64–73.PubMedPubMedCentral

23.

Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC, Magaña-Aquino M, Vargas-Morales JM, González-Amaro R, et al. Clinical pharmacokinetics of rifampin in patients with tuberculosis and type 2 diabetes mellitus: association with biochemical and immunological parameters. Antimicrob Agents Chemother. 2015;59:7707–14.PubMedCrossRef

24.

Nekoua MP, Fachinan R, Atchamou AK, Nouatin O, Amoussou-Guenou D, Amoussou-Guenou MK, et al. Modulation of immune cells and Th1/Th2 cytokines in insulin-treated type 2 diabetes mellitus. Afri Heal Sci. 2016;16:712–24. https://doi.org/10.4314/ahs.v16i3.11.CrossRef

25.

Nam HW, Cho YJ, Lim JA, Kim SJ, Kim H, Sim SY, et al. Functional status of immune cells in patients with long-lasting type 2 diabetes mellitus. Clin Exp Immunol. 2018;194:125–36.PubMedCrossRef

26.

Xiaohong L, Gao Y, Dong T, Yang L. Role of natural killer T (NKT) cells in type II diabetes-induced vascular injuries. Med Sci Monit. 2018;24:8322–32.CrossRef

27.

Guo H, Xu B, Gao L, Sun X, Qu X, Li X, et al. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. Exp Biol Med. 2012;237:556–62.CrossRef

28.

Kim JH, Park K, Lee SB, Kang S, Park JS, Ahn CW, et al. Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. J Diabetes Investig. 2019;10:1223–8.PubMedPubMedCentralCrossRef

29.

Tollerud DJ, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis. 1989;139:194–8.PubMedCrossRef

30.

Malarkannan S. Natural killer cells : development , maturation , and clinical utilization. Front Immunol. 2018;9:1–23.CrossRef

31.

Liu F, Wang H, Feng W, Ye X, Sun X, Jiang C, et al. Type 1 innate lymphoid cells are associated with type 2 diabetes. Diabetes Metab. 2019;45:341–6. https://doi.org/10.1016/j.diabet.2018.08.005.PubMedCrossRef

32.

Ukah TK, Cattin-Roy AN, Chen W, Miller MM, Barik S, Zaghouani H. On the role IL-4/IL-13 heteroreceptor plays in regulation of type 1 diabetes. J Immunol. 2017;199:894–902.PubMedPubMedCentralCrossRef

33.

McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22:276–82.CrossRef

34.

Rattik S, Engelbertsen D, Wigren M, Ljungcrantz I, Östling G, Persson M, et al. Elevated circulating effector memory T cells but similar levels of regulatory T cells in patients with type 2 diabetes mellitus and cardiovascular disease. Diab Vasc Dis Res. 2019;16:270–80.PubMedCrossRef

35.

Lynch LA, O’Connell JM, Kwasnik AK, Cawood TJ, O’Farrelly C, O’Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity. 2009;17:601–5.PubMedCrossRef

36.

Mxinwa V, Nyambuya TM, Dludla PV, Nkambule BB. The role of innate lymphoid cells and T helper cell activation in type 2 diabetic patients: a protocol for a systematic review and meta-analysis. Syst Rev. 2019;8:1–4.CrossRef

37.

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodologi …. J Epidemiol Community Health. 1998;52:377.PubMedPubMedCentralCrossRef

38.

Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011;11:22. https://doi.org/10.1186/1471-2288-11-22.PubMedPubMedCentralCrossRef

Title: Natural killer cell levels in adults living with type 2 diabetes: a systematic review and meta-analysis of clinical studies
Authors: Vuyolwethu Mxinwa
Phiwayinkosi V. Dludla
Tawanda M. Nyambuya
Kabelo Mokgalaboni
Sithandiwe E. Mazibuko-Mbeje
Bongani B. Nkambule
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Diabetes
Type 2 Diabetes
Published in: BMC Immunology / Issue 1/2020
Electronic ISSN: 1471-2172
DOI: https://doi.org/10.1186/s12865-020-00378-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

A software package for immunologists to learn simulation modeling

Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis

Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 αdependent, o2 sensing, molecular switch

Diagnostic value of serum soluble triggering expressed receptor on myeloid cells 1 (sTREM-1) in suspected sepsis: a meta-analysis

Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells

The impact of Clonorchis sinensis infection on immune response in mice with type II collagen-induced arthritis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage